Biogen says goodbye to Vounatsos and remaining Aduhelm hopes
The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?
Covid-19 takes its toll on medtechs’ efficiency
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
Roche remains big pharma’s biggest R&D spender
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
Bristol’s buy moves it to the top of the sales charts
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
After six years Bellicum admits it’s not ready for prime time
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
Medtechs that book the most sales per employee face the greatest losses
Welcome to the calm before the Covid-19 storm.
